Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients

Respiratory Medicine

Volumn 108, Issue 10, 2014, Pages 1498-1507

  Wedzicha, Jadwiga A ^a   Dahl, Ronald ^b   Buhl, Roland ^c   Schubert Tennigkeit, Agnes ^d   Chen, Hungta ^d   D'Andrea, Peter ^d   Fogel, Robert ^d   Banerji, Donald ^d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Glycopyrronium; Indacaterol; Pooled analysis; QVA149; Safety; Tiotropium

Indexed keywords

CORTICOSTEROID; GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; PLACEBO; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT; INDAN DERIVATIVE; QUINOLONE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRY POWDER INHALER; FEMALE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART DISEASE; HOSPITALIZATION; HUMAN; INHALER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT SAFETY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

AGED; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLYCOPYRROLATE; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RISK FACTORS; SCOPOLAMINE DERIVATIVES; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84908339443     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.07.011     Document Type: Article

References (39)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2014 At: http://www.goldcopd.org [accessed 08.05.14]
2. National Clinical Guideline Centre (NICE). Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary and secondary care 2010 At: http://guidance.nice.org.uk/CG101/Guidance [accessed 22.02.13]
3. G.J. Rodrigo, J.A. Castro-Rodriguez, and V. Plaza Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review Chest 136 4 2009 1029 1038
4. S. Singh, Y.K. Loke, and C.D. Furberg Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis JAMA 300 12 2008 1439 1450
5. H.S. Nelson, S.T. Weiss, E.R. Bleecker, S.W. Yancey, and P.M. Dorinsky The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol Chest 129 1 2006 15 26
6. P.M. Calverley, J.A. Anderson, B. Celli, G.T. Ferguson, C. Jenkins, and P.W. Jones Cardiovascular events in patients with COPD: TORCH study results Thorax 65 8 2010 719 725
7. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 15 2008 1543 1554
8. W. Vincken, J. Aumann, H. Chen, M. Henley, D. McBryan, and P. Goyal Efficacy and safety of co-administration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study Int J Chron Obstruct Pulmon Dis 9 2014 215 228
9. D.A. Mahler, A. D'Urzo, E.D. Bateman, S.A. Ozkan, T. White, and C. Peckitt Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison Thorax 67 9 2012 781 788
10. J.A. van Noord, J.L. Aumann, E. Janssens, J.J. Smeets, J. Zaagsma, and A. Mueller Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms Respir Med 104 7 2010 995 1004
11. D.P. Tashkin, J. Pearle, D. Iezzoni, and S.T. Varghese Formoterol and tiotropium compared with tiotropium alone for treatment of COPD COPD 6 1 2009 17 25
12. E.D. Bateman, G.T. Ferguson, N. Barnes, N. Gallagher, Y. Green, and M. Henley Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eur Respir J 42 2013 1484 1494
13. J.A. Wedzicha, M. Decramer, J.H. Ficker, D.E. Niewoehner, T. Sandstrom, and A.F. Taylor Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study Lancet Respir Med 1 3 2013 199 209
14. R. Dahl, K.R. Chapman, M. Rudolf, R. Mehta, P. Kho, and V.K. Alagappan Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study Respir Med 107 10 2013 1558 1567
15. R. Buhl, L.J. Dunn, C. Disdier, C. Lassen, C. Amos, and M. Henley Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD Eur Respir J 38 4 2011 797 803
16. K.R. Chapman, S.I. Rennard, A. Dogra, R. Owen, C. Lassen, and B. Kramer Long-term safety and efficacy of indacaterol, a long-acting beta(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study Chest 140 1 2011 68 75
17. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, and C. Lassen Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2 2011 273 279
18. G. Feldman, T. Siler, N. Prasad, D. Jack, S. Piggott, and R. Owen Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study BMC Pulm Med 10 2010 11
19. P.J. Barnes, S.J. Pocock, H. Magnussen, A. Iqbal, B. Kramer, and M. Higgins Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design Pulm Pharmacol Ther 23 3 2010 165 171
20. A. D'Urzo, G.T. Ferguson, J.A. van Noord, K. Hirata, C. Martin, and R. Horton Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respir Res 12 2011 156
21. E. Kerwin, J. Hebert, N. Gallagher, C. Martin, T. Overend, and V.K. Alagappan Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur Respir J 40 5 2012 1106 1114
22. C.F. Vogelmeier, E.D. Bateman, J. Pallante, V.K. Alagappan, P. D'Andrea, and H. Chen Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study Lancet Respir Med 1 1 2012 51 60
23. R. Dahl, D. Jadayel, V.K. Alagappan, H. Chen, and D. Banerji Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study Int J Chron Obstruct Pulmon Dis 8 2013 501 508
24. European Public Assessment Report (EPAR) Ultibro Breezhaler. At: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002679/human-med-001691.jsp. [accessed on 26.02.14].
25. J.F. Donohue, C. Fogarty, J. Lotvall, D.A. Mahler, H. Worth, and A. Yorgancioglu Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2 2010 155 162
26. M. Kinoshita, S.H. Lee, L.W. Hang, M. Ichinose, M. Hosoe, and N. Okino Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study Respirology 17 2 2012 379 389
27. W. Yao, C. Wang, and N. Zhong Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study Respirology 2014 10.1111/resp.12211 [Epub ahead of print]
28. M. Sekiya, T. Kawayama, and Y. Fukuchi Safety and efficacy of NVA237 once daily in Japanese patients: the GLOW4 trial Presented at European Respiratory Society Congress 2012 Abstract number 853970
29. K. Asai, Y. Minakata, and K. Hirata QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: the ARISE study Presented at European Respiratory Society Congress 2013 Poster number P3392
30. D.M. Caldwell, A.E. Ades, and J.P. Higgins Simultaneous comparison of multiple treatments: combining direct and indirect evidence BMJ 331 7521 2005 897 900
31. H. Mullerova, A. Agusti, S. Erqou, and D.W. Mapel Cardiovascular comorbidity in chronic obstructive pulmonary disease: systematic literature review Chest 144 4 2013 1163 1178
32. C. Schneider, U. Bothner, S.S. Jick, and C.R. Meier Chronic obstructive pulmonary disease and the risk of cardiovascular diseases Eur J Epidemiol 25 4 2010 253 260
33. D.P. Tashkin Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial Expert Rev Respir Med 4 3 2010 279 289
34. B. Celli, M. Decramer, I. Leimer, U. Vogel, S. Kesten, and D.P. Tashkin Cardiovascular safety of tiotropium in patients with COPD Chest 137 1 2010 20 30
35. A.G. Mathioudakis, P. Kanavidis, V. Chatzimavridou-Grigoriadou, I.P. Gialmanidis, S.G. Amanetopoulou, and E. Christopoulou Tiotropium HandiHaler improves the survival of patients with COPD: a systematic review and meta-analysis J Aerosol Med Pulm Drug Deliv 27 1 2014 43 50
36. G.J. Rodrigo, J.A. Castro-Rodriguez, L.J. Nannini, M.V. Plaza, and E.A. Schiavi Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis Respir Med 103 10 2009 1421 1429
37. M. Cazzola, A. Segreti, and P. Rogliani Comparative effectiveness of drugs for chronic obstructive pulmonary disease Drugs Today 48 12 2012 785 794
38. H. Worth, K.F. Chung, J.M. Felser, H. Hu, and P. Rueegg Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD Respir Med 105 4 2011 571 579
39. V.C. Chung, P.H. Ma, D.S. Hui, W.W. Tam, and J.L. Tang Indacaterol for chronic obstructive pulmonary disease: systematic review and meta-analysis PLoS One 8 8 2013 e70784